Oxaprozin

Cat. No.: HY-B0808
CAS No.: 21256-18-8
Molecular Formula: C₁₈H₁₅NO₃
Molecular Weight: 293.32
Target: COX; NF-κB
Pathway: Immunology/Inflammation; NF-κB
Storage:
- Powder
  - -20°C: 3 years
  - 4°C: 2 years
- In solvent
  - -80°C: 6 months
  - -20°C: 1 month

SOLVENT & SOLUBILITY

In Vitro
DMSO : ≥ 100 mg/mL (340.92 mM)
* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions

<table>
<thead>
<tr>
<th>Solvent Concentration</th>
<th>1 mg</th>
<th>5 mg</th>
<th>10 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 mM</td>
<td>3.4092 mL</td>
<td>17.0462 mL</td>
<td>34.0925 mL</td>
</tr>
<tr>
<td>5 mM</td>
<td>0.6818 mL</td>
<td>3.4092 mL</td>
<td>6.8185 mL</td>
</tr>
<tr>
<td>10 mM</td>
<td>0.3409 mL</td>
<td>1.7046 mL</td>
<td>3.4092 mL</td>
</tr>
</tbody>
</table>

In Vivo
1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.5 mg/mL (8.52 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 2.5 mg/mL (8.52 mM); Clear solution
3. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.5 mg/mL (8.52 mM); Clear solution

BIOLOGICAL ACTIVITY

Description
Oxaprozin is an inhibitor of both COX-1 and COX-2 with IC₅₀s of 2.2 μM and 36 μM for human platelet COX-1 and IL-1-stimulated human synovial cell COX-2, respectively. Oxaprozin also inhibits the activation of NF-κB.

IC₅₀ & Target
<table>
<thead>
<tr>
<th>COX-1</th>
<th>COX-2</th>
<th>NF-κB</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.2 μM (IC₅₀)</td>
<td>36 μM (IC₅₀)</td>
<td></td>
</tr>
</tbody>
</table>
In Vitro

Oxaprozin induces apoptosis in a dose-dependent manner. Oxaprozin increases caspase-3 activity in the activated but not in the resting condition. NF-κB activation is inhibited by 50 μM Oxaprozin. Oxaprozin inhibits activation of the IKK system induced by the reagent IκBα[1]. Oxaprozin dose dependently increase CD40L-treated monocyte apoptosis. 100 μM Oxaprozin induces the strongest proapoptotic effect. 100 μM Oxaprozin significantly increases CD40L-treated monocyte apoptosis. Oxaprozin treatment inhibits CD40L-induced Akt and NF-κB (p65) phosphorylation[2].

PROTOCOL

Kinase Assay[2]

Caspase 3 activity in the presence or absence of 200 ng/mL CD40L plus 1 μg/mL CD40L enhancer and 100 μM Oxaprozin is performed. The enzymatic activity is spectrophotometrically determined for 60 minutes at 405 nm assuming an extinction coefficient of 8.8×10^3 M^1/cm[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Assay[2]

Purified monocytes are resuspended at 10^6/mL and cultured for 48 hours. In selective experiments, cells are cultured in the presence or absence of 50 μM PD98059, 1 μM SB203580, 50 μM LY294002, 20 μM SN-50, 50 μM Ac-DEVD-CHO, different doses (5, 10, 50, 100 μM) of Oxaprozin, 100 μM ibuprofen,100 μM indomethacin, or 100 μM naproxene. Percentages of apoptotic cells are measured by both fluorescence microscope and flow cytometer[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES
